Skip to content

A Prospective, Randomized, Controlled Clinical Study of Bupivacaine Liposomes in Transversus Abdominis Plane Block

A Prospective, Randomized, Controlled Clinical Study of Bupivacaine Liposomes in Transversus Abdominis Plane Block

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600116158
Enrollment
Unknown
Registered
2026-01-06
Start date
2026-01-16
Completion date
Unknown
Last updated
2026-01-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

transversus abdominis plane block

Interventions

Bupivacaine Liposome Group:Transversus abdominis plane block using 266g of bupivacaine liposomes diluted to 40ml
Ropivacaine Group:Transversus abdominis plane block using 100mg ropivacaine diluted to 40ml

Sponsors

Puyang Oilfield General Hospital
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 40 Years

Inclusion criteria

Inclusion criteria: 1. ASA class I–II 2. Aged 20–40 years 3.BMI 18–28 kg/m² 4.No history of neurological disorders or infection at the puncture site 5. No severe cardiovascular, pulmonary, hepatic, renal, or immune system diseases 6. No history of allergy to related anesthetics 7. Willing to participate in the study and signed informed consent.

Exclusion criteria

Exclusion criteria: 1. Severe coagulation dysfunction; 2. Preoperative neurological deficits or neurological disorders; 3. Postoperative hemoglobin <80 g/L or critically ill patients admitted to the ICU postoperatively; 4. Cases where anesthesia was unsatisfactory, necessitating a change in anesthesia method.

Design outcomes

Secondary

MeasureTime frame
Effective PCA Press Count;

Primary

MeasureTime frame
VAS score;

Countries

China

Contacts

Public ContactWei Zhou

Puyang Oilfield General Hospital

zhouweimz@163.com+86 136 6306 1292

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026